CD22限制性表达于B细胞系，且能与其配体或相应抗体结合后以内化的方式进入细胞。这种特征使其成为利用抗体-药物偶联物（antibody-drug conjugate，ADC）治疗恶性血液肿瘤极具吸引力的靶点。ADC是将强细胞毒性的药物通过连接子与特异性抗体偶联而成的一种新型抗肿瘤药物，其利用单克隆抗体的强特异性和内吞性，引导药物直接进入靶细胞。此文综述了靶向CD22 ADC的靶点、抗体、连接子和药物的特点，以及近年来进入临床试验的靶向CD22 ADC的最新研究进展。

The CD22 molecule is restrictively expressed on the surface of B-lineage cells, and can enter cells through constitutive internalization once binding its ligand or antibody. Due to its characteristic, CD22 molecule becomes an attractive biological target for treatment of hematologic malignancies by antibody-drug

conjugates (ADCs). ADC consists of strong cytotoxic drugs conjugated to specific antibodies via linker. It takes advantage of the specificity and endocytosis of monoclonal antibody to guide drugs directly into target cells. In this article, the characteristic of targets, antibodies, linkers, and drug of CD22-targeting ADCs, as well as research progress of ADCs targeting CD22 which entered clinical trials in recent years are summarized.